Correct staging of pancreatic cancer is paramount, as treatment is stage specific. However, minimally invasive tools to facilitate staging are lacking. DNA promoter hypermethylation is a hallmark of cancer. The aim of this study is to evaluate promoter hypermethylation in cell-free DNA as a prognostic marker for stage classification of pancreatic adenocarcinoma. Consecutive patients with pancreatic adenocarcinoma were prospectively included. Plasma samples were obtained before diagnostic workup and treatment. Patients were staged according to the TNM classification. Methylation-specific PCR of 28 genes was performed. Prognostic prediction models for staging of pancreatic adenocarcinoma were developed by multivariable logistic regression analysis using stepwise backwards elimination. Ninety-five patients with pancreatic adenocarcinoma were included. The mean number of hypermethylated genes was identical for stage I, II and III disease (7.09 (95% CI; 5.51-8.66), 7.00 (95% CI; 5.93-8.07) and 6.77 (95% CI; 5.08-8.46)), respectively, and highly significantly different from stage IV disease (10.24 (95% CI; 8.88-11.60)). The prediction model (SEPT9v2, SST, ALX4, CDKN2B, HIC1, MLH1, NEUROG1, and BNC1) enabled the differentiation of stage IV from stage I-III disease (AUC of 0.87 (cut point 0.55; sensitivity 74%, specificity 87%)). Model (MLH1, SEPT9v2, BNC1, ALX4, CDKN2B, NEUROG1, WNT5A, and TFPI2) enabled the differentiation of stage I-II from stage III-IV disease (AUC of 0.82 (cut point 0.66; sensitivity 73%, specificity 80%)). Cell-free DNA promoter hypermethylation has the potential to be blood-based prognostic markers for pancreatic adenocarcinoma, as panels of hypermethylated genes enables the differentiation according to cancer stage. However, further validation is required.
10%-20% of patients can be offered surgical treatment. 4 Due to a more advanced cancer stage than initially anticipated, 20% of these patients are non-resectable at the time of surgery. 5 It would be of great benefit to the patients and the clinicians if additional minimal invasive tools to facilitate cancer staging were available.
Currently, CA-19-9 is the only clinically implemented blood-based test for pancreatic cancer. However, it lacks sufficient sensitivity and specificity to work as a diagnostic marker. [6] [7] [8] Nevertheless, studies suggest that CA-19-9 has prognostic relevance, as an elevated level is more common in advanced cancer stages. However, 10% of the population lacks the ability to produce CA-19-9 because of Le a-b-blood group status, which is an essential drawback. 9 During neoplastic progression of pancreatic cancer, multiple genetic and epigenetic changes arise. In contrast to genetic modifications, epigenetic modifications do not chance the DNA sequence. Epigenetic modifications change the DNA conformation; consequently, the expression of genes will change. DNA hypermethylation is an epigenetic mechanism, which consists of the addition of a methyl (CH3) residue on cytosines preceding guanosines (CpGs). [10] [11] [12] [13] Hypermethylation in the promoter regions leads to a condensed chromatin structure, which may result in gene downregulation or silencing associated with carcinogenesis. 10, 11, 14, 15 Studies have shown that DNA hypermethylation in pancreatic cancer tissue is a potential predictor of pancreatic cancer progression. 16, 17 DNA hypermethylation is detectable in plasma-derived cell-free DNA. One hypothesis is that hypermethylation of cell-free DNA is tumour stage specific and useable as a biomarker for staging pancreatic cancer. [18] [19] [20] We previously performed a literature review to identify genes aberrantly methylated and detectable in cell-free DNA from patients with pancreatic cancer. 20 Additionally, we examined the hypermethylation of plasma-derived cell-free DNA as a diagnostic marker for pancreatic adenocarcinoma and found a panel of eight genes that could discriminate patients with pancreatic adenocarcinoma from patients with benign pancreatic disease or symptoms mimicking upper gastrointestinal cancer. 21 The aim of this present study was to develop prognostic prediction models for pancreatic adenocarcinoma according to stage, based on a selected panel of hypermethylated promoter regions in plasma-derived cell-free DNA.
Methods

Study design
This study was conducted as an observational predictive study of patients with pancreatic adenocarcinoma who were admitted to the Department of Gastrointestinal Surgery, Aalborg University Hospital, from February 2008 until February 2011. 22 All participants gave written informed consent. The study was registered in ClinicalTrials.gov (NCT02079363) and approved by the Research Ethics Committee for the North Denmark Region (N-2013037).
Participants
Consecutive patients with pancreatic adenocarcinoma were prospectively included. Blood samples were drawn on admission before the diagnostic work-up and before treatment.
Patients were excluded if they had previous (within three years) or concomitant cancer, known congenital thrombophilia, previous venous thromboembolism, connective tissue disease, or ongoing anticoagulant therapy. American Society of Anaesthesiologists (ASA) score and WHO performance status (PS) were registered at time of inclusion. Data from the same patients were used in a previous study. 21 
Diagnosis and stage classification
CT and PET scans of thorax and abdomen were performed in the diagnostic work-up of all patients. Histopathological analysis of biopsy specimens obtained by percutaneous, endoscopic or laparoscopic ultrasound confirmed the cancer diagnosis. Patients were staged according to TNM classification 7 th Edition. 3 T and N categories were determined by histopathological analysis for patients who underwent intended curative surgery. If surgery was not performed, the final clinical decision determined the T and N categories. All patients were discussed at a multidisciplinary team conference, where consensus was reached on staging and treatment. 22 Blood sampling and analytical method Blood samples were obtained by skilled technicians. 23 EDTA plasma for methylation analysis was centrifuged 20 min (4000 rpm) at 48C and stored within two hours after sampling in a biobank at 2808C until further analysis. 21 All methylation analyses were performed blinded by a single skilled laboratory scientist. Extraction and deamination of cell-free DNA was performed as described by our group.
21,24
What's new? The treatment of pancreatic cancer depends on accurate staging, and while tools to assist with tumor evaluation are available, the development of novel minimally invasive approaches could greatly facilitate staging. Here, analyses of plasma-derived cell-free DNA show that promoter hypermethylation accumulates during neoplastic progression and changes with advancing cancer stage, with the mean number of hypermethylated genes in stage IV differing significantly from stages I, II, and III. Prognostic prediction models successfully differentiated patients according to cancer stage, suggesting that cell-free DNA hypermethylation could serve as a blood-based prognostic marker for pancreatic cancer, being used alongside existing clinical tools.
A first-round PCR amplification was conducted to expand the amount of relevant deaminated DNA. A mix of outer methylation-specific primers for all the investigated promoter regions was used (Supporting Information Table 1 ). Afterwards, a second round of PCR was carried out using each of the inner methylation-specific primers and methylationspecific probes in individual reactions (Supporting Information Table 1 ). 21 The gene panel consisted of 28 selected promoter sequences (Supporting Information Table 2 ). The gene selection was previously described by our group. 21 We used hemimethylated MEST transcript variant 1 as the reference gene in both the first and second round PCR.
Outcome
The primary outcome of the prognostic prediction models was cancer stage. 
Statistical analysis methods
Patients. Patients were divided into groups according to the TNM classification. Level of cell-free DNA. We calculated the median level (ng/ ml) of cell-free DNA for each group according to cancer stage. Nonparametric Wilcoxon rank sum test was used for comparison of the groups.
Hypermethylated genes. The total number of hypermethylated genes was calculated for each patient. The Kendall's rank test was used for correlation analysis of the total number of hypermethylated genes and level of cell-free DNA.
The mean number of hypermethylated genes and the (exact) 95% confidence interval (CI) were calculated for each group. The means were compared as numerical data with nonparametric Wilcoxon rank sum test. A p values < 0.05 was considered statistically significant, unless otherwise was stated.
Prognostic prediction model development. were selected for further analysis. 3. Model selection: To select the relevant variables, stepwise backwards elimination in logistic regression models was performed using 0.10 as the significance level for removal from the model. In the backward elimination algorithm, variables were eliminated one by one to identify the optimal combination of variables representing the highest predictive power. In the stepwise procedure, the least significant variable was eliminated from the variable combination. For each intermediate model, the AUC value was calculated. 4. Determination of the best model: Model performance according to the AUC combined with model complexity determined the best model.
Interactions between the variables:
The significance of interactions between all pairs of variables was assessed in the final model. Interactions with a p-value < 0.01 were considered statistically significant. 6. Validation: "Leave pair out cross validation" was used 25 to account for optimism in the internal validation of discriminative model performance (measured by the AUC). "Hosmer-Lemeshow" test was performed for calibration performance. 7. Probability score: For each patient, a probability score was calculated. All data were analysed using STATA 14.0 software [StataCorp LP, Texas].
All authors had full access to the study data and had reviewed and approved the final manuscript.
Results
Patients
Ninety-five patients with confirmed pancreatic adenocarcinoma were included in the study. Descriptive data of the patients is shown in Table 1 .
Validation of dichotomous data
No difference in the distribution of D Ct was observed between stage I, II vs stage III, IV and stage I, II, III vs stage IV, indicating that no significant amount of information was lost by dichotomizing the genes as hypermethylated or nonmethylated, regardless of the observed Ct value.
Level of cell-free DNA
There was no significant difference in the median level of cell-free DNA according to stage of pancreatic adenocarcinoma (Supporting Information Table 3 and Supporting Information Figure 1 ). In addition, the correlation between the level of cell-free DNA and number of hypermethylated genes was slightly positive with a Kendall's s of 0.28 (p values < 0.001).
Hypermethylated genes
The hypermethylation frequencies of each gene in each cancer stage are listed in Supporting Information (Table 2 ).
Prognostic prediction model stage I, II, III vs IV
In the following analyses, patients with stage I, II and III (n 5 53) disease were pooled and compared to stage IV (n 5 42) disease to develop a model to differentiate between pancreatic adenocarcinoma patients with and without distant metastasis. There was a significant difference between stage I, II, III and stage IV in the hypermethylation frequency of seven genes (ALX4, BNC1, HIC1, SEPT9v2, SST, TFPI2 and TAC1) ( Table 3 ). There was no statistically significant difference in gender, age, ASA score or PS between the groups. There was a tendency towards more patients with distant metastasis having an ASA score of three and a PS of two, despite that ASA score, PS, age and gender were excluded from the further analysis. All genes with an individual p values < 0.3 (17 genes out of 28 examined genes) (Table 3) were included in the multivariable logistic regression model.
Stepwise backwards elimination was performed and the stepwise selection of genes was clarified with the corresponding AUC (Fig. 1a) . The initial model (model 1) with the 17 genes had an AUC of 0.89 (Fig. 1a) . Removing the nine least significant genes form the model, leaving eight genes in the panel (Model 10; SEPT9v2, SST, ALX4, CDKN2B, HIC1, MLH1, NEUROG1, BNC1), resulted in an AUC of 0.87 ( Fig. 1a and  1b) . Model 10 was determined as the final model (probability cut point of 0.55; sensitivity 74%, specificity 87%, positive predictive value 82%, negative predictive value 81% and accuracy 81%) (Fig. 1b) , as it only contained a limited number of variables, and leaving out the 12 least significant variables only resulted in a minimal loss of predictive power. There were no statistically significant interactions in Model 10. The model was well calibrated (p values 5 0.18) and had an estimated optimism in AUC of 0.05. The median probability score for stage I, II and III cancer patients was of 0.24 compared to 0.74 for patients with stage IV disease (p values < 0.001).
Prognostic prediction model stage I, II vs III, IV
Patients with stage I or II (n 5 40) disease were combined and compared to stage III or IV (n 5 55) disease to develop a model to differentiate between patients with potentially resectable pancreatic adenocarcinoma (stage I and II) and patients with non-resectable pancreatic adenocarcinoma (stage III and IV). There were statistically significant differences (p values < 0.05) between stage I, II and stage III, IV in the hypermethylation frequencies of four genes (ALX4, BNC1, Sept9v2, and SST) (Table 3) , and no statistically ( Bold marks the genes with statistically significant difference (p<0.05) in hypermethylation frequency between the groups. Gene variables with a p-value < 0.3 in the simple logistic regression analysis were included in the multivariable logistic regression analysis.
*Genes which could not be evaluated by logistic regression, as one of the groups did not contain any patients with hypermethylation of this specific gene.
Cancer Genetics and Epigenetics significant difference in gender, age, ASA score or PS. All genes with an individual p values < 0.3 (14 genes out of 28 examined genes) (Table 3) were included in the multivariable logistic regression analysis using stepwise backwards elimination. Model 1 with 14 genes had an AUC of 0.83 (Fig. 2a) . Removing the six least significant genes from the model, leaving eight genes in the panel (Model 7; MLH1, SEPT9v2, BNC1, ALX4, CDKN2B, NEUROG1, WNT5A, and TFPI2) resulted in an AUC of 0.82 ( Fig. 2a and 2b ). Model 7 was determined as the final model to differentiate between stage I, II and stage III, IV disease (probability cut point of 0.66; sensitivity 73%, specificity 80%, positive predictive value 83%, negative predictive value 68% and accuracy 76%). There were no statistically significant interactions between variables in model 7. The model was well calibrated (p values 5 0.28) and had an estimated optimism in AUC of 0.06. The median probability score for stage I and II cancer patients was of 0.37 compared to 0.70 for patients with stage III and IV disease (p values < 0.001).
Prognostic prediction model stage I, IIa vs IIb
It was not possible to differentiate pancreatic adenocarcinoma with lymph node positive disease (stage IIb) from lymph node negative disease (stage I or IIa) based on the hypermethylation profile (data not shown).
Prognostic prediction model stage I, II vs III
The hypermethylation profile was not able to differentiate non-resectable primary tumours (T4) from potentially resectable primary tumours (T1-T3) (data not shown).
Discussion
We examined cell-free DNA promoter hypermethylation of 28 genes in plasma of patients with pancreatic adenocarcinoma according to staging. As shown previously, hypermethylated cell-free DNA is detectable in all stages of pancreatic adenocarcinoma. 20, 25 However, in our study, patients with stage IV disease stand out by having significantly higher numbers of hypermethylated genes in cell-free DNA compared to stage I, II and III disease. This suggests an accumulation of hypermethylated promoter regions during cancer development and progression. Distant metastasis has previously been associated with a larger amount of cell-free DNA. 26 However, in our study, no difference in the level of cell-free DNA was observed between the various cancer stages. The association between advanced stage pancreatic adenocarcinoma and a greater number of hypermethylated genes in cell-free DNA has not previously been described. Two small studies on cell-free DNA hypermethylation in pancreatic cancer were not able to show this association. 18, 27 Consistent with our results, Sato et al. demonstrated the presence of aberrant methylations in pancreatic tissue from early precursor lesions (pancreatic intraductal neoplasia (PanIN)-1). They describe an increase in methylation prevalence from PanIN-1 to PanIN-3, suggesting DNA hypermethylations progressively increase during neoplastic progression. 28 Our study is only able to demonstrate the difference between non-metastatic and metastatic disease. Unfortunately, and probably due to insufficient power, we are not able to demonstrate that hypermethylations in cell-free DNA likewise accumulate from stage I to stage III disease.
We found that promoter hypermethylation of plasmaderived cell-free DNA of seven genes (ALX4, BNC1, HIC1, SEPT9v2, SST, TFPI2, and TAC1) was significantly associated with pancreatic adenocarcinoma with distant metastases. To our knowledge, this has not previously been described. Zhao et al. found HIC1 hypermethylation to be significantly more prevalent in pancreatic cancer tissue stage III and IV compared to stage I and II. 29 Hypermethylation of TFPI2 in cellfree DNA has also been associated with distant metastasis in colorectal cancer 30 and in metastatic melanoma. 31 In contrast to our findings, hypermethylation of ALX4 has been detected in colorectal cancer tissue, but equally at all stages of the disease. 32 Likewise, SEPT9v2 has been detected in colorectal cancer tissue 32 and in cell-free DNA at the same frequency in all stages of the disease, suggesting SEPT9v2 hypermethylation occurs earlier in the carcinogenesis of colorectal cancer compared to pancreatic cancer development.
A recent study on colorectal cancer described a panel of ten genes (including BNC1) that was more frequently hypermethylated in tissue from adenomas and early stage colorectal cancer compared to tissue from metastatic colorectal cancer. 33 This study demonstrated that hypermethylations in primary tumour tissue may differ from hypermethylations present in metastatic tissue, and furthermore suggests that hypermethylations not only accumulate but also change throughout cancer progression. As none of the genes examined in our study had the potential to work as a single marker for staging pancreatic adenocarcinoma, we developed two prognostic prediction models: a panel of genes to differentiate stage I, II, III from stage IV and a panel to distinguish stage I, II from stage III, IV pancreatic adenocarcinoma. The panels overlap with six genes out of eight. We previously analysed the same 28 genes as a diagnostic marker for pancreatic adenocarcinoma, 21 and found an alternative gene panel that differentiates between patients with benign and malignant pancreatic disease. Only BNC1 was recurring in the diagnostic and prognostic gene panels. This suggests that DNA promoter hypermethylation changes during the development of pancreatic adenocarcinoma and specific hypermethylations are of importance at different cancer stages.
The two prognostic prediction models described in our study are able to differentiate patients with pancreatic adenocarcinoma according to stage. In particular, the gene panel to distinguish patients with distant metastasis (stage IV) from patients without distant metastasis (stage I, II and III) has a very high performance. To our knowledge, we are the first to develop prognostic prediction models for staging of pancreatic adenocarcinoma based on hypermethylated cell-free DNA. Both prognostic tests have highly clinical relevance, as the tests have the potential to be used as supplements to existing clinical tools in stage classification and in the difficult evaluation of resectability. The tests have the great advantage of being blood-based and thereby minimal invasive, only causing limited discomfort. Blood-based markers are of great benefit to the patients compared to tissue-based markers, which are invasive and entail a risk of complications. Blood-based markers for pancreatic disease are of the utmost importance, as tumours in the pancreas may occur in tissues that are difficult to access due to their location deep in the upper part of the abdomen. Furthermore, small tumour size may limit the ability to sample adequate tissue, and the biopsies may not sufficiently represent the tumour.
Limitations
We designed the study as an explorative study, only showing data from a single patient cohort. We are aware that to substantiate our results, testing the models in independent cohorts is considered the gold standard for biomarker validation and is necessary before the tests can be applied in a clinical setting. However, it was impossible for us to reach this standard during the development phase, as pancreatic adenocarcinoma is a relatively rare disease. To assess the optimism of the models we instead performed internal validation "leave pair out cross validation".
In the subgroup analyses, some of the groups contained limited numbers of patients, which could result in loss of power and a lack of difference in methylation profiles between stage I, IIa vs IIb and stage I, II vs III.
For methylation analysis, we performed methylationspecific PCR, which is a quantitative method using hemimethylated MEST transcript variant 1 as a reference gene. 24 Unfortunately, our study lacked power to conduct a quantitative statistical analysis. Consequently, we analysed hypermethylation as a binary variable, which led to the loss of quantitative information.
The method we used for methylation analysis did not provide information regarding numbers or proportion of methylated CpGs in the promoter sequence. Subsequent DNA sequencing of the PCR products could have provided detailed information about methylated CpGs. 34 However, this was not possible in our set up. We discovered at the end of the analysis that the use of UNG (Invitrogen) had a tendency to lower the sensitivity compared to the use of COD UNG (ArcticZymes). All of the samples in our study were analysed using UNG (Invitrogen). The lack of sample material made it impossible to repeat the analysis using COD UNG (ArcticZymes).
Strengths
Our study also has several strengths. We tested plasmaderived cell-free DNA hypermethylation of a broad gene panel in a large group of consecutive pancreatic adenocarcinoma patients who were included prospectively. Blood samples were obtained before the diagnosis and before treatment. All patients had a systematic and comprehensive diagnostic work-up to ensure the correct diagnosis and stage classification.
The methylation analysis was performed blinded and based on an optimized method of bisulfite treatment, which has a high recovery of cell-free methylated DNA and thereby improved sensitivity compared to previous methods. Furthermore, the optimized method results in DNA deamination in less than two hours, making it potentially usable in a clinical setting. 24 Prognostic biomarkers for pancreatic cancer are lacking. We developed two prognostic gene panels for pancreatic adenocarcinoma, which are blood-based and, as mentioned above, have several advantages compared to tissue-based markers.
Conclusion
In conclusion, promoter hypermethylation of plasma-derived cell-free DNA is detectable even in early stage pancreatic adenocarcinoma. Hypermethylations accumulate and change during neoplastic development and with aggravating cancer stage. With high performance, panels of genes are able to differentiate patients with pancreatic adenocarcinoma according to cancer stage. Based on our study, cell-free DNA hypermethylation has the potential to be blood-based prognostic markers for pancreatic adenocarcinoma and a supplement to existing clinical tools in stage classification and evaluation of resectability. However, external validation is required to substantiate the results.
